Navigation Links
Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
Date:2/16/2011

mplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.  The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233 in addition to new funding from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.  For additional information on Chimerix, please visit '/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
2. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
3. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
4. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
5. Chimerix to Present at Upcoming Investor Conferences
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
8. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
9. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
10. Chimerix Joins International Network of Organizations to Cure Malaria
11. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive menstrual ... available new FDA approved system in the last 14 years, and the only endometrial ... (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the ...
(Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... ... 28, 2015 , ... Pittcon is pleased to announce that ... on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments Show) ... scientific instruments show which will be held at International Conference Hall in Makuhari ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... pharmaceutical and biotechnology research and development outsourcing company, today ... for the fourth quarter and full year 2010 ended ... host a conference call to discuss the results at ...
... – EMD Serono, Inc., an affiliate of Merck ... a complete response letter (CRL) from the U.S. ... drug application (NDA) for Cladribine Tablets, EMD Serono,s ... therapy for relapsing-remitting multiple sclerosis (MS). ...
... Communications , the team have created a microscope which shatters ... beating the diffraction limit of light. Previously, the standard ... 0.001 millimetres clearly. But now, by combining an ... the Manchester researchers can see 20 times smaller 50 ...
Cached Biology Technology:ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 3EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 4Microscope could 'solve the cause of viruses' 2
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Saudi Arabia Biomedical Sensors market is estimated at $0.23 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... scientists at the Broad Institute of MIT and Harvard announced ... that can connect human diseases with potential drugs to treat ... human cells. Called the "Connectivity Map," the new tool and ... Science and in separate publications in the September 28 immediate ...
... your way through an unfamiliar neighborhood to a friend's ... is adept at adapting. It can make decisions based ... new information. , The nature of such sophisticated decision ... high-level processing, has been "poorly studied and little understood," ...
... sequence of a 5-million-year-old retrovirus and shown that it is ... ancestor of a large family of mobile DNA elements, some ... study, which is the first to generate an infectious retrovirus ... a breakthrough for the field of retrovirus research. The ...
Cached Biology News:Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3Where we change our mind 2Scientists resuscitate a 5 million-year-old retrovirus 2